Oncimmune Holdings PLC Grant of Options and PDMR Dealing (4292F)

TIDMONC

RNS Number : 4292F

Oncimmune Holdings PLC

04 November 2022

4 November 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Grant of Options and PDMR Dealing

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that on 3 November 2022, options ("Options") to subscribe for an aggregate of 196,809 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") were granted to Adam Hill (Chief Executive Officer), Matthew Hall (Chief Financial Officer) and Ron Kirschner (General Counsel & Company Secretary) as follows:

 
 Name            Position                    No. of Options   Exercise 
                                              Awarded          Price per 
                                                               Share 
 Adam Hill       Chief Executive Officer        125,000       GBP0.50 
                --------------------------  ---------------  ----------- 
 Matthew Hall    Chief Financial Officer         30,000       GBP0.50 
                --------------------------  ---------------  ----------- 
 Ron Kirschner   General Counsel & Company       30,000       GBP0.50 
                  Secretary 
                --------------------------  ---------------  ----------- 
 

The Options have been granted under the 2016 Share Option Plan, have an exercise price of GBP0.50, being the closing price of Ordinary Shares in Oncimmune Holdings plc on 2 November 2022, and vest annually in five equal parts from the date of grant until the fifth anniversary of grant.

Following this grant, each of Adam Hill, Matthew Hall and Ron Kirschner hold the following interests in the Company:

 
 Name             Number of Ordinary   Number of Options 
                   Shares currently     held post grant 
                         held 
 Adam Hill              73,872             3,615,862 
                 -------------------  ------------------ 
 Matthew Hall           11,935              809,554 
                 -------------------  ------------------ 
 Ron Kirschner          1,652               556,738 
                 -------------------  ------------------ 
 

This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation and serves as notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them.

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                               1. Adam Hill 
                                           2. Matthew Hall 
                                           3. Ron Kirschner 
      ---------------------------------  ---------------------------------------------- 
       Reason for the notification 
  2 
      --------------------------------------------------------------------------------- 
 a)    Position/status                    1. Chief Executive Officer 
                                           2. Chief Financial Officer 
                                           3. General Counsel & Company Secretary 
      ---------------------------------  ---------------------------------------------- 
 b)    Initial notification               Initial notification 
        /Amendment 
      ---------------------------------  ---------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------------- 
 a)    Name                               Oncimmune Holdings plc 
      ---------------------------------  ---------------------------------------------- 
 b)    LEI                                213800HCYIWT6YPI1I02 
      ---------------------------------  ---------------------------------------------- 
       Details of the transaction(s): section to be repeated for 
  4     (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      --------------------------------------------------------------------------------- 
 a)    Description                        Ordinary Shares of GBP0.01 each 
        of the financial 
        instrument, 
        type of instrument 
 
       Identification                     ISIN: GB00BYQ94H38 
        code 
 
 b)    Nature of the                      Grant of options 
        transaction 
      ---------------------------------  ---------------------------------------------- 
 c)    Price(s) and 
        volume(s) 
                                          -----------------------  ------------------ 
                                           Price(s)                 Volume(s) 
                                          -----------------------  ------------------ 
    1. GBP0.50                                                      125,000 
   --------------------------------------------------------------  ------------------ 
    2. GBP0.50                                                      30,000 
   --------------------------------------------------------------  ------------------ 
    3. GBP0.50                                                      30,000 
   --------------------------------------------------------------  ------------------ 
 
 d)    Aggregated 
        information 
 
  - Aggregated                       N/A - single transaction 
   volume 
 
  - Price 
 
 e)    Date of the                        3 November 2022 
        transaction 
      ---------------------------------  ---------------------------------------------- 
 f)    Place of the                       Outside a trading venue 
        transaction 
      ---------------------------------  ---------------------------------------------- 
 

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

[phone]

Media enquiries:

Freelands Finance

John Goold

[e-mail]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBKQBDABDDNDK

(END) Dow Jones Newswires

November 04, 2022 12:16 ET (16:16 GMT)